Patients receiving VK2735 achieved up to 12.2% mean body weight reduction over 13 weeks, compared to just 1.3% with placebo. How clinically meaningful is this degree of weight loss in such a short timeframe, and how does it compare to currently available oral and injectable incretin therapies?

The trial reported statistically significant weight reductions as early as Week 1 for doses above 15 mg. How important is this rapid onset of effect in terms of patient adherence, satisfaction, and long-term treatment success?

The VENTURE-Oral study demonstrated a clear dose-response, with progressive weight loss observed up to the highest tested dose of 120 mg and no plateau at Week 13. What does this suggest about the potential for even greater efficacy with longer dosing periods or optimized titration strategies?

An exploratory cohort rapidly titrated to 90 mg and then stepped down to 30 mg daily demonstrated maintained weight loss. How does this signal inform the potential role of VK2735 in long-term weight management strategies compared to therapies that require continuous high-dose administration?

Despite robust efficacy, VK2735 showed a manageable safety profile with 98–99% of treatment-emergent GI adverse events categorized as mild or moderate. How does this tolerability profile compare to other GLP-1/GIP agonists, and could it make VK2735 more suitable for broader adoption, particularly in patients hesitant about injectable treatments?

With semaglutide and tirzepatide already setting a high efficacy bar, where do you see VK2735 fitting within the competitive landscape? Could the once-daily oral formulation be a differentiator for certain patient populations or prescriber preferences?

Given VK2735’s dual GLP-1/GIP mechanism and metabolic effects, how promising is its potential in related indications such as type 2 diabetes, NAFLD, or other weight-related comorbidities?

Based on these Phase 2 results, what key aspects should Viking prioritize when designing Phase 3 trials? Do you expect maintenance strategies, broader patient inclusion criteria, or combination regimens to play a significant role in the development plan?